A Clinical Study of 6MW3211 Injection in the Treatment of Advanced Malignant Neoplasm
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This study is a single arm, non-randomized, open label, multiple doses phase I/II
international, multicenter clinical trial to evaluate safety, tolerability, PK/PD,
immunogenicity and preliminary efficacy in subjects with advanced malignant neoplasm. The
study is consisted of two stages: dose escalation and clinical expansion.
Only Phase I has been submitted to US FDA,and the protocol number is still the same as
6MW3211-2021-CP101.The US title is : A Phase 1, First-in-Human (FIH), Multicenter,
Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and
Pharmacodynamics of 6MW3211 in Patients with Advanced Malignancies .